Gilead granting royalty free temporary license to 5 generic manufacturers to service 127 poor nations. Interesting strategy - allows Gilead to focus their limited supply to richer companies that can afford the drug while creating a solution for poorer countries. Diversion may be an issue - will be interesting to see how they control that
IMO

https://www.google.com/amp/s/www.marketwatch....8844329201